Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Neurobiology and Treatment of Reading Disability in NF-1
This study is currently recruiting participants.
Verified by National Institute of Neurological Disorders and Stroke (NINDS), August 2008
Sponsors and Collaborators: Kennedy-Krieger Research Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by: National Institute of Neurological Disorders and Stroke (NINDS)
ClinicalTrials.gov Identifier: NCT00624234
  Purpose

The goal of this trial is to determine if children with neurofibromatosis type 1 who have reading disabilities respond the same way—both behaviorally and neurobiologically—to specialized treatment programs as children with idiopathic reading disabilities do, and to determine which intervention is best for particular learner profiles.


Condition Intervention
Neurofibromatosis Type 1
Reading Disabilities
Behavioral: Tutoring Program I
Behavioral: Tutoring Program II

Genetics Home Reference related topics: familial encephalopathy with neuroserpin inclusion bodies neurofibromatosis type 1 neurofibromatosis type 2
MedlinePlus related topics: Neurofibromatosis
Drug Information available for: Amphetamine Methamphetamine Benzocaine
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind (Subject), Parallel Assignment, Efficacy Study
Official Title: Neurobiology and Treatment of Reading Disability in Neurofibromatosis Type 1 (NF-1)

Further study details as provided by National Institute of Neurological Disorders and Stroke (NINDS):

Primary Outcome Measures:
  • Improvement in basic reading skills as assessed by standard educational assessments (e.g., Woodcock Johnson Psychoeducational Battery - 3rd Edition; WJ-III) [ Time Frame: 0, 5, 10, and 15 hours ] [ Designated as safety issue: No ]

Estimated Enrollment: 180
Study Start Date: February 2006
Estimated Study Completion Date: March 2011
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
Tutoring Program I
Behavioral: Tutoring Program I
Tutoring Program I is a structured multi-sensory program that is designed to gradually present the range of sounds and letters with focus on accuracy of phonological concepts and application of those concepts in phrases and sentences. The instruction uses a sequenced defined lesson plan with accuracy and automaticity criteria for skill progression. A range of manipulative and kinesthetic activities is outlined to maintain learner engagement in the intensive intervention design.
2: Experimental
Tutoring Program II
Behavioral: Tutoring Program II
Tutoring Program II is designed to teach visual and speech elements of reading separately at first, and then bring them together for maximum efficiency. The program uses the idea of teaching concepts about the structure of words. For example, students transfer the rules they have learned about one vowel or structure to another without specific instructions on the new one. Tutoring Program II incorporates pictures and activities to help remember strategies for increasing basic reading skills. Speed drills are also used for development of decoding automaticity.
3: No Intervention
Control group

Detailed Description:

The most common concern of parents of children with neurofibromatosis type 1 (NF-1) is learning disabilities (LD). Approximately one half of all children with NF-1 have LD—the most debilitating and common of which are reading disabilities.

The purpose of this study is to determine if children with NF-1 who have reading disabilities respond the same way—both behaviorally and neurobiologically—to specialized treatment programs known to improve the decoding deficits in children with idiopathic reading disabilities. The trial will also determine which intervention is best for particular learner profiles. The overall purpose of this research is to gain a deeper understanding of the characteristics and treatment of reading disabilities in NF-1.

In the trial, researchers will compare children with NF-1 who show weaknesses in reading to children with reading disabilities of no known cause (idiopathic) using two different interventions and behavioral and neurobiological measures. Both interventions focus on teaching sound-symbol relationships, but vary in terms of relative emphasis on verbal versus visual methods of teaching.

Scientists hope findings from the trial will advance knowledge about the best therapies for LD in children with NF-1. And, by further refining how children with NF-1 who have reading disabilities are similar (or different) to children with idiopathic reading disabilities, the researchers may be able to learn if reading interventions that address areas other than decoding will also benefit children with NF-1. Also, by understanding the similarities and/or differences in the neuropsychological and neurobiological profiles of children with NF-1 who have reading disabilities, and those without, scientists will be able to refine the cognitive phenotype and neurobiological characteristics of NF-1, which will further understanding of central nervous system abnormalities in NF-1.

  Eligibility

Ages Eligible for Study:   8 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

This study will be open to all individuals, ages 8 to 17 years, who meet eligibility criteria regardless of race, gender, or socioeconomic status.

  • The Reading Disabilities group (including those with NF-1) is defined by scoring equal to or less than the 25th percentile on measures of basic word reading skills.
  • The Control group (including those with NF1) is defined by scoring equal to or above the 40th percentile on the average of the Letter Word Identification and Word Attack subtests from the WJ-III.

Exclusion Criteria:

Any child, regardless of which group he/she is recruited for, will be excluded if he/she meets any of the following criteria (determined during phone screening, medical review, and during testing):

  • is in foster care;
  • previous diagnosis of mental retardation;
  • known uncorrectable visual impairment;
  • history of known neurological disorder (e.g., epilepsy, spina bifida, cerebral palsy, traumatic brain injury);
  • documented hearing impairment greater than 25 dB loss in either ear;
  • medical contraindication to MRI procedures, if participating in MRI (including exposure to metal and pregnancy);
  • individuals known to have an IQ below 70;
  • history or presence of a pervasive developmental disorder;
  • during the DICA-IV parents indicate the presence of any severe psychiatric diagnoses or pervasive developmental disorder.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00624234

Contacts
Contact: Lindsay Goldberg 443-923-9326 readingresearch@kennedykrieger.org

Locations
United States, Maryland
Kennedy Krieger Institute, F. M. Kirby Research Center for Functional Brain Imaging Recruiting
Baltimore, Maryland, United States, 21205
Contact: Laurie E. Cutting, Ph.D.     443-923-9250     cutting@kennedykrieger.org    
Contact: Martha Bridge Denckla     443-923-9250        
Principal Investigator: Laurie E. Cutting, Ph.D.            
Principal Investigator: Martha Bridge Denckla, M.D.            
Principal Investigator: Sheryl L. Rimrodt, M.D.            
Sponsors and Collaborators
Kennedy-Krieger Research Institute
Investigators
Principal Investigator: Laurie E. Cutting, Ph.D. Kennedy Krieger Institute, Johns Hopkins University, Johns Hopkins University School of Medicine
Principal Investigator: Martha Bridge Denckla, M.D. Kennedy Krieger Institute, Johns Hopkins University, Johns Hopkins University School of Medicine
Principal Investigator: James J. Pekar, Ph.D. Kennedy Krieger Institute, Johns Hopkins University School of Medicine, F. M. Kirby Research Center for Functional Brain Imaging
Principal Investigator: Sheryl L. Rimrodt, M.D. Kennedy Krieger Institute, Johns Hopkins University, Johns Hopkins University School of Medicine
  More Information

additional study information  This link exits the ClinicalTrials.gov site

Responsible Party: Kennedy Krieger Institute ( Laurie E. Cutting, Ph.D., Principal Investigator, F. M. Kirby Research Center for Functional Brain Imaging )
Study ID Numbers: R01NS49096, NF1-R01
Study First Received: February 25, 2008
Last Updated: August 12, 2008
ClinicalTrials.gov Identifier: NCT00624234  
Health Authority: United States: Federal Government

Keywords provided by National Institute of Neurological Disorders and Stroke (NINDS):
neurofibromatosis type 1
reading disabilities
NF-1
learning disabilities
tutoring intervention

Study placed in the following topic categories:
Benzocaine
Neurodegenerative Diseases
Neurofibromatosis 1
Neurofibromatosis type 1
Methamphetamine
Neoplastic Syndromes, Hereditary
Heredodegenerative Disorders, Nervous System
Neurofibroma
Genetic Diseases, Inborn
Neuromuscular Diseases
Peripheral Nervous System Diseases
Neurofibromatoses
Amphetamine
Nerve Sheath Neoplasms
Neurocutaneous Syndromes

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Histologic Type
Nervous System Diseases
Neoplasms, Nerve Tissue

ClinicalTrials.gov processed this record on January 16, 2009